{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:38:45Z","timestamp":1786991925419,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1099452"],"award-info":[{"award-number":["APP1099452"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jcrc.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T22:32:27Z","timestamp":1530657147000},"page":"164-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Emergence of antimicrobial resistance to piperacillin\/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-7167","authenticated-orcid":false,"given":"Sofie A.M.","family":"Dhaese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"De Kezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Callant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerina","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"De Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcrc.2018.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","article-title":"Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0010","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00134-015-3719-z","article-title":"Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination","volume":"5","author":"Gin","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: a review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijantimicag.2009.11.015","article-title":"Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates\u2014a multicentre, observational survey in critically ill patients","volume":"35","author":"Vogelaers","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0040","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14787210.2017.1338139","article-title":"Optimizing \u03b2-lactams treatment in critically-ill patients using pharmacokinetics\/pharmacodynamics targets: are first conventional doses effective?","volume":"15","author":"Delattre","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2013.10.021","article-title":"Prolonging \u03b2-lactam infusion: a review of the rationale and evidence, and guidance for implementation","volume":"43","author":"MacVane","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0050","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/jac\/dkv165","article-title":"The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs","volume":"70","author":"Tabah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0055","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10096-012-1803-7","article-title":"A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals","volume":"32","author":"Buyle","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cmi.2016.04.019","article-title":"The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for \u03b2-lactam administration and therapeutic drug monitoring among critically ill patients in France","volume":"22","author":"Charmillon","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0065","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of \u03b2-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CCM.0000000000002210","article-title":"Right dose, right now: customized drug dosing in the critically ill","volume":"45","author":"Roberts","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0080","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.02177-15","article-title":"Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 1","volume":"60","author":"Drusano","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0090","series-title":"Clinical and Laboratory Standards Institute document M7-A7","isbn-type":"print","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014seventh edition","author":"CLSI. Clinical Laboratory and Standards Institute","year":"2006","ISBN":"https:\/\/id.crossref.org\/isbn\/1562385879"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/cid\/cix612","article-title":"Predicting resistance to piperacillin-tazobactam, cefepime and meropenem in septic patients with bloodstream infection due to gram-negative bacteria","volume":"65","author":"Vazquez-Guillamet","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13613-017-0296-z","article-title":"Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration","volume":"7","author":"Yusuf","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0105","doi-asserted-by":"crossref","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Ser B (Stat Methodol.) (n.d.);73:273\u2013282.","DOI":"10.1111\/j.1467-9868.2011.00771.x"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1214\/13-AOS1175","article-title":"A significance test for the lasso","volume":"42","author":"Lockhart","year":"2014","journal-title":"Ann Stat"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0115","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/AAC.00334-06","article-title":"The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance","volume":"51","author":"Tam","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0120","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1128\/AAC.03505-14","article-title":"Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0125","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1128\/AAC.01486-06","article-title":"Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection","volume":"51","author":"Stearne","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0130","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","article-title":"Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa","volume":"49","author":"Tam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2018.07.003_bb0135","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.47.5.1604-1613.2003","article-title":"In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus","volume":"47","author":"Firsov","year":"2003","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944118301904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944118301904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T06:44:33Z","timestamp":1569048273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944118301904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":27,"alternative-id":["S0883944118301904"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2018.07.003","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergence of antimicrobial resistance to piperacillin\/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}